Nanoveu Limited
ACN 624 421 085
Level 45, 108 St Georges Terrace
Perth WA, 6000 Australia
+61 8 6244 9095
www.nanoveu.com

ASX RELEASE **11 July 2025**

ASX: NVU

Strategic Placement Raises A$2.0 Million To Accelerate Commercialisation of ECS-DoT Chip

Funding received to support 16nm tape-out, live drone trials, and rollout of EMASS's modular AIoT platform

Highlights

- Firm commitments received to raise $2 million (before costs) via a Placement to a restricted group of high net worth investors, at $0.055 per Share.
- Strong demand from a combination of new and existing sophisticated and professional investors following recent announcement of 16nm ECS-DoT SoC development.
- Company now well-funded to complete tape-out of 16nm SoC and rollout of EMASS's modular AIoT platform.
- Phase 2 drone trials underway targeting additional simulated endurance across a range of different flight environments, with results expected in the current quarter.
- Strengthened balance sheet positions Nanoveu for accelerated global expansion across EMASS's leading edge semiconductor technologies, smart coatings, and glasses-free 3D solutions.
- Nanoveu is progressing its application to dual-list on the U.S. OTCQB Market in support of its commercial expansion strategies.

Nanoveu Limited (ASX: NVU) ("Nanoveu" or the "Company"), a technology innovator across advanced semiconductor, visualisation, and materials science applications, is pleased to announce that it has overnight received firm commitments to raise $2.0 million (before costs) through a placement of 36,363,637 fully paid ordinary shares ("**New Shares**") at an issue price of $0.055 per share, from new and existing sophisticated, professional, and high net worth investors ("**Placement**").

The Placement follows strong inbound interest from both existing and new investors, driven by Nanoveu's recent announcement of a major development milestone, the commencement of 16nm ECS-DoT SoC synthesis in partnership with the Centre of Nanoelectronics and Devices (CND), and the launch of EMASS's Modular AIoT Development Kit[1].

The Placement ensures Nanoveu is well-capitalised to complete its 16nm tape-out, expand real-world testing, and accelerate market entry across multiple verticals.

As the Company advances toward commercialisation of its ECS-DoT platform, it is also progressing through Phase 2 of its structured drone testing program. Building on earlier success that demonstrated a 33%[2] increase in simulated flight time, the Company now aims to achieve targeted 40-70% improved flight performance under various conditions with results anticipated within the current quarter.

Dr David Pevcic, Executive Chairman of NVU, commented: "*We're extremely pleased at the strong support for this Placement from both existing and new investors. The interest we've seen following the 16nm SoC announcement has been exceptional, and this funding enables us to finalise key milestones, including the tape-out of our 16nm chip and broader rollout of EMASS's AIoT platform. With our 22nm silicon already in hand and our 16nm architecture ready for fabrication, this is a pivotal moment in our journey toward scalable commercial deployment. We look forward to updating shareholders on our continued progress."*

[1] Refer to ASX announcement dated 9 July 2025
[2] Refer to ASX announcement 1 July 2025

Use of Proceeds

Funds raised from the Placement will be directed towards the development and commercialisation of Nanoveu's EMASS semiconductor technologies, the expansion of EyeFly3D™ commercial activities, and the advancement of Nanoshield™ Solar field trials in Morocco and the UAE. Additional funds will support working capital to drive operational growth and cover the costs associated with the Placement.

These investments are expected to substantially accelerate Nanoveu's commercialisation roadmap across its major divisions and capitalise on significant growth opportunities in edge computing, digital 3D content, and renewable energy solutions.

Details of the Placement

Under the Placement the Company will issue a total of 36,363,637 Shares at an issue price of $0.055 per under the Company's existing ASX Listing Rule 7.1 and 7.1A placement capacities.

The offer price of $0.055 per new share represents a:

- 6.78% discount to the last traded price of $0.059 per share on 10 July 2025, being the last date that the Company's shares traded on the ASX prior to the date of this announcement;
- 4.33% premium to the 5-day volume weighted average price ("VWAP") price of $0.0527 per share up to an including 10 July 2025,
- 10.32% premium to the 10-day VWAP of $0.050 per share up to an including 10 July 2025; and
- 12.39% premium to the 15-Day VWAP of $0.049 per share up to an including 10 July 2025.

The Placement was jointly led by Evolution Capital and 62 Capital ("Joint Lead Managers"). The Joint Lead Managers will receive a fee of 6% of the gross amount raised, together with 5,000,000 Listed Options (exe $0.045, exp 09/05/2027) and 5,000,000 unlisted options exercisable at $0.10 per option on or before the date that is 3 years from the date the options are issued for services provided as joint lead managers.

The Placement will be completed within Nanoveu's existing ASX Listing Rule 7.1 and 7.1A placement capacities. Settlement of the New Shares is expected to occur on or around 22 July 2025, with the broker options anticipated to be completed shortly after.

This announcement has been authorised for release by the Board of Directors.

-ENDS-

Nanoveu Media
Alfred Chong, Nanoveu MD and CEO
P: +65 6557 0155
E: info@nanoveu.com

Nanoveu Investors
Namratha Gunnala, Automic Group
P: +61 2 8072 1400
E: namratha.gunnala@automicgroup.com.au

About Nanoveu Limited

Further details on the Company can be found at https://nanoveu.com/.

EMASS is a pioneering technology company specialising in the design and development of advanced systems-on-chip (SoC) solutions. These SoCs enable ultra-low-power, AI-driven processing for smart devices, IoT applications, and 3D content transformation. With its industry-leading technology, EMASS will enhance Nanoveu's portfolio, empowering a wide range of industries with efficient, scalable AI capabilities, further positioning Nanoveu as a key player in the rapidly growing 3D content, AI and edge computing markets.

EyeFly3D™ is a comprehensive platform solution for delivering glasses-free 3D experiences across a range of devices and industries. At its core, EyeFly3D™ combines advanced screen technology, sophisticated software for content processing, and now, with the integration of EMASS's ultra-low-power SoC, powerful hardware.

Nanoshield™ is a self-disinfecting film that uses a patented polymer of embedded Cuprous nanoparticles to provide antiviral and antimicrobial protection for a range of applications, from mobile covers to industrial surfaces. Applications include, *Nanoshield™ Marine*, which prevents the growth of aquatic organisms on submerged surfaces like ship hulls, and *Nanoshield™ Solar*, designed to prevent surface debris on solar panels, thereby maintaining optimal power output.

Forward Looking Statements This announcement contains 'forward-looking information' that is based on the Company's expectations, estimates and projections as of the date on which the statements were made. This forward-looking information includes, among other things, statements with respect to the Company's business strategy, plans, development, objectives, performance, outlook, growth, cash flow, projections, targets and expectations and related expenses. Generally, this forward-looking information can be identified by the use of forward-looking terminology such as 'outlook', 'ambition', 'anticipate', 'project', 'target', 'potential', 'likely', 'believe', 'estimate', 'expect', 'intend', 'may', 'mission', 'would', 'could', 'should', 'scheduled', 'will', 'plan', 'forecast', 'evolve' and similar expressions. Persons reading this announcement are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the Company's actual results, level of activity, performance, or achievements to be materially different from those expressed or implied by such forward looking information.